Products sold as “Kamagra for women” are labelled with the same active substance as the male version — sildenafil citrate, usually 100 mg. The evidence on sildenafil in women is mixed: it has not been shown to raise desire (libido), and two landmark studies found benefit only in specific subgroups. None of these products is registered as a medicine in the EU.
The label sounds like a feminist answer to the blue pill. The reality is less revolutionary: the same active substance, a pink box, and more open questions. “Kamagra for women” is a marketing name for products declaring sildenafil, not a registered treatment. Let us take them apart without the sugar coating.
What “Kamagra for women” is and how it differs from the male version
Under the name Kamagra for women — sometimes called “female Kamagra” — sellers offer products that declare the same active substance as the male Kamagra: sildenafil citrate, usually 100 mg. The difference is marketing rather than composition: pink colouring, packaging aimed at women, and occasionally an Oral Jelly form. According to labels and sales materials, they are made by the Indian company Ajanta Pharma; on the market they also appear under names such as “Lovegra” or “Kamagra Woman”. In gel form it appears as Kamagra Oral Jelly for women.
The colour of a pill and the text on a box do not confirm what is inside. Kamagra in any form is not registered as a medicine in the EU, and its sale in the target markets is not authorised. More on the whole Kamagra product family can be found in the Kamagra tablets guide.
How sildenafil acts in the female body
Sildenafil is a PDE5 inhibitor. It blocks the enzyme that breaks down the substance supporting blood flow, thereby increasing pelvic blood flow. In theory it can improve genital sensitivity, blood flow and lubrication — which is why it was studied as a possible help for female sexual arousal disorder (FSAD).
Research on sildenafil in women gives mixed results. A 2003 study by Berman and colleagues (The Journal of Urology) found significant improvement in postmenopausal women with FSAD without concurrent desire disorder; in women with concurrent hypoactive sexual desire disorder (HSDD), the benefit was not confirmed. A 2008 study by Nurnberg and colleagues (JAMA) showed that sildenafil may help women with sexual dysfunction induced by antidepressants (SSRIs). In 2024, reports appeared in the professional literature about a topical sildenafil cream at 3.6% concentration that showed improvement in some FSAD measures.
Critical fact: sildenafil does not increase libido — the desire for sex. It affects blood flow, not the chemical processes in the brain behind desire. This is the most common myth: a tablet will not fix long-term low desire that is tied to hormones, psychology, stress, relationships and overall health.
How sildenafil works in the body generally is explained in the complete sildenafil guide.
Registration status in the EU
Kamagra in any form — tablets, Oral Jelly, effervescent tablets, “for women” or “for men” — is not registered as a medicine in the EU and is not authorised for sale in the member states where this store operates. Regulators repeatedly warn against the internet sale of unregistered erectile-dysfunction products, and they classify Kamagra among them.
The difference from registered sildenafil medicines (such as Viagra and its generic equivalents available in EU pharmacies) is fundamental: a registered medicine has a traceable registration number, a marketing authorisation holder, controlled composition and an approved SmPC/PIL. Unregistered Kamagra has none of these guarantees.
Why does this matter in practice? Without registration there is no quality control, the manufacturing conditions and origin are unknown, and falsification is a real risk. How to tell a falsified product from a registered medicine is covered in the article on fake erectile dysfunction drugs. Registration status can be checked in the databases of your national medicines authority and the European Medicines Agency.
Side effects and contraindications
Sildenafil has the same side-effect profile in women as in men. The following information is factual; for any concern, speak to a doctor or pharmacist.
Common side effects:
- headache
- facial redness, hot flushes
- nasal congestion
- visual disturbance (blurred vision, light sensitivity, colour discrimination problems)
- digestive upset, diarrhoea
- dizziness
Serious risks:
- a marked fall in blood pressure
- interaction with nitrates (heart medicines) — can be life-threatening
- priapism (a prolonged, painful erection) — though extremely rare in women
Sildenafil should not be taken by:
- people with cardiovascular disease
- people with low blood pressure
- people taking nitrates or nitric-oxide-based medicines
- pregnant and breastfeeding women
- people allergic to sildenafil
Urgent warning: if chest pain, a serious allergic reaction, or a sudden worsening of vision or hearing appears after use, seek medical help immediately.
Is there an officially approved “female Viagra”?
There are registered medicines intended for women — but they work completely differently from sildenafil, and none is available in the EU.
- Addyi (flibanserin) — approved by the US FDA for premenopausal women with hypoactive sexual desire disorder (HSDD). It acts on chemical processes in the brain, not on blood flow. It has no EU marketing authorisation.
- Vyleesi (bremelanotide) — approved by the US FDA; an injectable acting on melanocortin receptors. It has no EU marketing authorisation.
The key difference: Addyi and Vyleesi are approved medicines with clinical studies, a precisely defined indication and controlled manufacturing. Kamagra and Lovegra have no such approved indication — they are unregistered products without a documented clinical profile. European registration rules are described on the European Medicines Agency site.
What to check before any decision
- For health questions, talk to a gynaecologist or general practitioner — not a forum or a blog.
- Check the registration status of any medicine or product with the national medicines authority.
- The colour of a pill says nothing about its safety or efficacy.
- The difference between a registered medicine and an unregistered product is verifiable quality, composition and oversight.
- No tablet replaces communication with a partner or dealing with the health and psychological causes of low desire.
For general sexual health without sales shortcuts, see the article on morning erection. If you are comparing specific products sold under the “Kamagra for women” label — for example the Kamagra Oral Jelly Woman listing in our catalogue (For Women category) — check the composition, registration status and suitability for your body; availability of catalogue listings is limited while our compliance review continues. Comparison is only the first step; the decision belongs to you and your doctor.
Frequently asked questions
Is Kamagra for women the same as Kamagra for men?
The declared active substance is the same — sildenafil citrate. The difference is marketing (pink colour, packaging aimed at women), not composition. Neither version is registered as a medicine in the EU.
Does Kamagra for women increase libido?
No. Sildenafil affects blood flow, not desire. Libido is complex — it is tied to hormones, psychology, stress, relationships and overall health. A tablet will not fix it.
Is Kamagra for women legal in the EU?
No. Kamagra in any form is not registered as a medicine in the EU. Its sale in the target markets is not authorised.
What are the most common side effects?
Headache, facial redness, nasal congestion, visual disturbance and digestive upset. If serious symptoms appear (chest pain, allergic reaction, loss of vision), seek medical help immediately.
Is there an officially approved “female Viagra”?
In the US, Addyi (flibanserin) and Vyleesi (bremelanotide) are approved for low desire in women. Neither is available in the EU. They work differently from sildenafil.
What should a woman do if she has taken Kamagra?
A single accidental dose usually does not cause serious harm. Common side effects may appear (headache, redness, dizziness). For any unpleasant or persistent symptoms, contact a doctor.
Sources and methodology
Medical claims in this article are based on:
- Berman, J. R. et al. (2003). Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study. The Journal of Urology. PubMed
- Nurnberg, H. G. et al. (2008). Sildenafil treatment of women with antidepressant-associated sexual dysfunction: A randomized controlled trial. JAMA. PubMed
- European Medicines Agency (EMA)
You can read more about our editorial process on the editorial policy page.
Author: Testovic Source check date: 10 August 2026 Content prepared by Testovic. No independent doctor or pharmacist reviewer is documented. The article is informational — it does not make a diagnosis, replace a medical examination, or recommend a specific treatment. For health concerns, contact a doctor or pharmacist.